

For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

**UNITED THERAPEUTICS ANNOUNCES PROMOTION OF
DEAN BUNCE TO VICE PRESIDENT, REGULATORY AFFAIRS AND
MICHAEL WADE TO VICE PRESIDENT, DEVELOPMENT AND
MEDICAL AFFAIRS**

Research Triangle Park, NC, November 13, 2002: United Therapeutics Corporation (NASDAQ: UTHR) announced today the promotions of Dean Bunce to Vice President of Regulatory Affairs and Michael Wade, Ph.D. to Vice President of Development and Medical Affairs. Mr. Bunce joined United Therapeutics Corp. in 1999 and has over thirteen years of international regulatory affairs experience; Mr Bunce has been involved with over fourteen marketing applications and over 25 investigational applications in the cardiovascular, oncology, and antiviral therapeutic areas. Dr. Wade joined United Therapeutics in 1997 and has nearly ten years of drug development experience; Dr. Wade has led project teams in all phases investigating multiple therapeutic areas.

"I am extremely pleased to announce these promotions," said Roger Jeffs, PhD, United Therapeutics' President and Chief Operating Officer. "Dean Bunce has successfully orchestrated the regulatory approvals of Remodulin for pulmonary arterial hypertension in the US, Canada and Israel, along with associated filings in multiple other territories. Likewise, Dr. Wade has been one of the key individuals responsible for the clinical development of Remodulin since its infancy, and is currently responsible for all post-approval studies of Remodulin, including the Phase IV Flolan transition study and the critical limb ischemia development effort."

In his new position, Mr. Bunce will continue to be responsible for implementing United Therapeutics' worldwide regulatory strategy for its cardiovascular and anti-infective therapies. Dr. Wade will continue to be responsible for all post-marketing studies of Remodulin® (treprostinil sodium) Injection, United Therapeutics' therapy for the treatment of pulmonary arterial hypertension, and for progressing early stage compounds into and through clinical development.

United Therapeutics is a biotechnology company focused on combating cardiovascular, infectious and oncological diseases with unique therapeutic products.

* * *